Adial Files Azora Merger Financials: $44M IPR&D Charge, Going Concern Warning
ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.1× avg).
Summary
Adial's 8-K/A reveals Azora's audited financials: $282K cash, going concern warning, and a pro forma combined net loss of $64.5M driven by a $44.1M IPR&D charge.
Key Events · M&A and Partnerships · ADIL
-
Azora Financials Reveal Distress
Azora had $282K cash at Dec 31, 2025, a going concern warning, and an accumulated deficit of $9.4M. It raised $4M in convertible notes in March 2026 to stay afloat.
-
$44.1M Acquired IPR&D Charge
The pro forma income statement includes a $44.1M non-cash expense for acquired in-process R&D, reflecting the fair value of Azora's AT177 program, which is expensed immediately under asset acquisition accounting.
-
$6.1M Loss on Note Extinguishment
Azora's $5.5M in convertible notes were exchanged for pre-funded warrants, resulting in a $6.1M loss recorded in the pro forma statement of operations.
-
Pro Forma Net Loss of $64.5M for FY2025
Combined pro forma net loss for the year ended Dec 31, 2025 was $64.5M, driven by the IPR&D charge, note extinguishment loss, and $4.6M in transaction costs.
Analysis · ADIL · Life Sciences
This amendment delivers the audited financials of Azora and pro forma combined statements for the June 11 merger. The numbers are stark: Azora had just $282,000 in cash at year-end 2025, a going concern warning, and a $9.4 million accumulated deficit. The pro forma income statement shows a $44.1 million acquired in-process R&D expense and a $6.1 million loss on note extinguishment, driving a combined net loss of $64.5 million for 2025. The balance sheet reveals a $32.1 million warrant liability and a $39.6 million stockholders' deficit. These details materially change the risk profile of the merger — the acquired entity was deeply distressed, and the accounting treatment creates a massive one-time loss that wipes out equity.
At the time of this filing, ADIL was trading at $4.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.